Interim Report January - June 2007

Interim Report January - June 2007

KEY EVENTS DURING THE PERIOD

-Net revenues amounted to MSEK 15.2 (55.4)
-The loss after tax was MSEK 94.5 (loss: 9.3)
-Earnings per share amounted to a loss of SEK 6.80 (loss: 0.70)
-Orexo's Annual General Meeting was held on April 23 - the Board was reelected
-A patent for OX 17 was approved in Europe

SECOND QUARTER 2007

-Net revenues amounted to MSEK 8.8 (5.1)
-The loss after tax was MSEK 56.5 (loss: 24.6)
-Earnings per share amounted to a loss of SEK 4.06 (loss: 1.85)

KEY EVENTS AFTER THE PERIOD

-Orexo establishes sales force in Nordic markets, by entering into a joint
venture with ProStrakan


For report in full format, see enclosed link to pdf. 


For more information, please contact 
Zsolt Lavotha, President & CEO, Tel: +46 (0)18-780 88 12, e-mail:
zsolt.lavotha@orexo.se 

Claes Wenthzel, Executive Vice President and CFO, Orexo AB 
+46 (0)18 780 88 44, e-mail: claes.wenthzel@orexo.se 


TO THE EDITORS 

About Orexo 
Orexo is a pharmaceutical company which focuses on identifying suboptimal
therapeutic characteristics of existing products and developing more efficient
and effective delivery methods for them. By combining approved active substances
with Orexo´s drug delivery technologies it is possible to significantly enhance
their therapeutic value, such as providing quicker onset of action or ease of
administration. This business model is aimed at bringing products to market
faster with lower development risk and costs. 

Orexo, which has its global headquarters and development laboratories in Sweden,
currently operates across the world through development, licensing and
distribution agreements in all major markets. 

Orexo has a balanced portfolio with two products on the market, three in
registration and/or late stage clinical phase and two under formulation
development. 

Orexo is listed on the OMX Nordic List Mid Cap (ticker;ORX).